Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

Stathopoulos, George P.; Antoniou, D.; Dimitroulis, J.; Stathopoulos, J.; Marosis, K.; Michalopoulou, P.

doi:10.1007/s00280-011-1572-5

Cited by 88 publications

(50 citation statements)

References 31 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As this liposomal formulation is less toxic, preclinical and clinical studies made on NSCLC have shown that a 3-6 times higher dose than the standard dose of cisplatin resulted to a better anticancer effect with lower toxicity [24,25]. In our studies, no toxicity was observed with Lipoplatin ™ as measured by the mean survival time of the animals compared to controls, whatever the route of administration used.…”

Section: Discussionsupporting

confidence: 39%

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

et al. 2013

View full text Add to dashboard Cite

Treatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects which prevent use at higher dose that would otherwise improve the antineoplastic effect. To reduce toxicity, we propose to encapsulate the platinum drug in a liposome. We have also tested three methods of drug administration (intra-venous, intra-arterial and intra-arterial combined with blood brain barrier disruption) to determine which one optimizes the tumor cell uptake, limits the toxicity and delivers the best concomitance effect with radiotherapy. Cisplatin, oxaliplatin, their respective liposomal formulations, Lipoplatin ™ and Lipoxal ™ , and carboplatin were assessed in F98 glioma, orthotopically implanted in Fischer rats. We found that the modest accumulation of drugs in tumor cells after intra-venous injection was significantly improved when the intra-arterial route was used and further increased after the transient opening of the blood brain barrier with mannitol. The liposomal formulations have largely reduced the toxicity and have allowed a better exploitation of the anti-cancer activity of platinum agent. Although the liposomes Lipoplatin ™ and Lipoxal ™ have shown a similar ability to CIHR Author ManuscriptCIHR Author Manuscript CIHR Author Manuscript that of carboplatin, to accumulate in brain tumors, the highest additive effect with radiotherapy was obtained with carboplatin. We conclude that the intra-arterial infusion of carboplatin or Lipoxal ™ in concomitance with radiation therapy leads to the best tumor control as measured by an increase of mean survival time in Fischer rats implanted with the F98 glioma with a benefit in survival time of 13.4 and 6.5 days respectively compared to intra-venous.

show abstract

Section: Discussionsupporting

confidence: 39%

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Due to their reactive nature, most of the drugs are rapidly inactivated by binding to proteins or other molecules upon entering the organism and never reaching the tumor in an active form that is considered a major cause of much dose-limiting toxicity [39]. One approach to try and to circumvent these drawbacks is to encapsulate the drug in liposomes.…”

Section: +mentioning

confidence: 99%

Rhenium–platinum antitumor systems

Shtemenko¹,

Штеменко²

2017

Ukr.Biochem.J.

View full text Add to dashboard Cite

this review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium (III) design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; antianemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction

show abstract

“…Sterically stabilized lipospomal variants of doxorubicin and cisplatin are commercially available and have been shown to exhibit higher therapeutic efficacy or at least better tolerability than the free drugs. Both agents have so far been successfully tested against various solid tumors including breast cancer (Rivera 2003, O'Brien 2008), Kaposi's sarcoma (Coukell & Spencer 1997, Sharpe et al 2002, non-squamous non-small-cell lung cancer (Mylonakis et al 2009, Stathopoulos et al 2011, and pancreatic cancer (Stathopoulos et al 2006), among others. Recently, we have demonstrated an extraordinary uptake phenomenon of liposomes, specifically in adrenocortical tumor cells (Hantel et al 2010(Hantel et al , 2012.…”

Section: Introductionmentioning

confidence: 99%

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Hantel¹,

Jung²,

Mussack³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Owing to high relapse rates and early metastatic spread, prognosis in adrenocortical carcinoma (ACC) patients remains poor, highlighting the importance of developing new treatment alternatives for them. Recently, polychemotherapy regimens including etoposide, doxorubicin, and cisplatin together with mitotane (EDP-M) have been defined as the standard treatment for late-stage disease patients. Nevertheless, the administration of conventional cytostatic drugs is associated with severe and dose-limiting side effects. In an attempt to optimize existing clinical treatment regimens, in this study, we investigated the therapeutic efficacy of EDP-M in comparison with that of a paclitaxel-modified scheme (paclitaxel, doxorubicin, cisplatin plus mitotane (PDP-M)) in preclinical in vitro and in vivo models. In addition, based on an extraordinary uptake phenomenon of liposomes in ACC cells, we further evaluated liposomal variants of these protocols (etoposide, liposomal doxorubicin, liposomal cisplatin plus mitotane (LEDP-M) and nab-paclitaxel, liposomal doxorubicin, liposomal cisplatin plus mitotane (LPDP-M)). In vitro, PDP-M was more potent in the induction of apoptosis and inhibition of cell viability as well as cell proliferation than EDP-M. Following the administration of a single therapeutic cycle, we further demonstrated that LEDP-M and LPDP-M exerted significant antitumoral effects in vivo, which were not as evident upon EDP-M and PDP-M treatments. These results were confirmed in a long-term experiment, in which the highest and sustained antitumoral effects were observed for LEDP-M. In summary, liposomal cytostatic substances could represent a promising option that deserves testing in appropriate clinical protocols for the treatment of ACC patients.

show abstract

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

Cited by 88 publications

References 31 publications

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Rhenium–platinum antitumor systems

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Contact Info

Product

Resources

About